Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23703179 | 0.88 | ROCK2 (0.41) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL1844348 | 0.86 | ROCK2 (0.41) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL18617132 | 0.86 | ROCK2 (0.41) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL21121081 | 0.86 | ROCK2 (0.41) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL13354632 | 0.84 | GABRA1 (0.43) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL2546394 | 0.83 | ROCK2 (0.40) | ROCK2SCDELANEMGLLFAAH | |
| SCHEMBL20029212 | 0.81 | SCD (0.47) | ROCK2SCDMGLLBCHE | |
| SCHEMBL429675 | 0.81 | NR1H2 (0.43) | ROCK2SCDMGLLGPR119ALDH1A1 | |
| SCHEMBL23075458 | 0.80 | CYP17A1 (0.49) | ROCK2SCDMGLLGPR119 | |
| SCHEMBL17633410 | 0.79 | ROCK2 (0.44) | ROCK2SCDELANEFAAHGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4526304-A1 | INHIBITORS OF PARG | 858 Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023224998-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2010030810-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | ROCK2 773/4885SCD 719/4885ELANE 241/4885 |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | PARG, PLG, PTGIS | ROCK2 995/4885SCD 4286/4885ELANE 312/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | ROCK2 761/4885SCD 4417/4885ELANE 3280/4885 |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | PARG, PLG, PARN | ROCK2 1787/4885SCD 4211/4885ELANE 699/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | ROCK2 983/4885SCD 4384/4885ELANE 2505/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | ROCK2 3581/4885SCD 4024/4885ELANE 2501/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | ROCK2 1731/4885SCD 4252/4885ELANE 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.